| Literature DB >> 29339530 |
Leandro Kasuki1,2,3, Luiz Eduardo Wildemberg1,2, Mônica R Gadelha1,2,4.
Abstract
Acromegaly is associated with high morbidity and elevated mortality when not adequately treated. Surgery is the first-line treatment for most patients as it is the only one that can lead to immediate cure. In patients who are not cured by surgery, treatment is currently based on a trial-and-error approach. First-generation somatostatin receptor ligands (fg-SRL) are initiated for most patients, although approximately 25% of patients present resistance to this drug class. Some biomarkers of treatment outcome are described in the literature, with the aim of categorizing patients into different groups to individualize their treatments using a personalized approach. In this review, we will discuss the current status of precision medicine for the treatment of acromegaly and future perspectives on the use of personalized medicine for this purpose.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29339530 DOI： 10.1530/EJE-17-1006
Source DB: PubMed Journal: Eur J Endocrinol ISSN： 0804-4643 Impact factor: 6.664